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Abstract: Extravasation of circulating cancer cells is regulated by the intercellular/intracellular
signaling pathways that locally impair the endothelial barrier function. Co-cultures of human
umbilical vein endothelial cells (HUVECs) with lung adenocarcinoma A549 cells enabled us
to identify these pathways and to quantify the effect of fenofibrate (FF) on their activity.
A549 cells induced the disruption and local activation of endothelial continuum. These events
were accompanied by epidermal growth factor (EGF) up-regulation in endothelial cells. Impaired
A549 diapedesis and HUVEC activation were seen upon the chemical inhibition of connexin(Cx)43
functions, EGF/ERK1/2-dependent signaling, and RhoA/Rac1 activity. A total of 25 µM FF
exerted corresponding effects on Cx43-mediated gap junctional coupling, EGF production,
and ERK1/2 activation in HUVEC/A549 co-cultures. It also directly augmented endothelial
barrier function via the interference with focal adhesion kinase (FAK)/RhoA/Rac1-regulated
endothelial cell adhesion/contractility/motility and prompted the selective transmigration of
epithelioid A549 cells. N-acetyl-L-cysteine abrogated FF effects on HUVEC activation, suggesting
the involvement of PPARα-independent mechanism(s) in its action. Our data identify a novel
Cx43/EGF/ERK1/2/FAK/RhoA/Rac1-dependent signaling axis, which determines the efficiency of
lung cancer cell diapedesis. FF interferes with its activity and reduces the susceptibility of endothelial
cells to A549 stimuli. These findings provide the rationale for the implementation of FF in the therapy
of malignant lung cancers.
Keywords: fenofibrate; lung cancer; diapedesis; Cx43; EGF
1. Introduction
Lung cancer is one of the most frequently diagnosed cancers in Europe [1,2]. The five-year
survival rates of the patients with non-small-cell lung cancers (NSCLCs) are relatively low and reach
24% and 4% for advanced and metastatic NSCLCs, respectively. The high lethality of NSCLCs
predominantly results from the local and systemic dissemination of cancer cells through the respiratory
and vascular system. The metastatic cascade of NSCLC leads to the progressive deterioration of
respiratory functions and results in the formation of secondary tumors in the brain, kidneys, and bones.
NSCLC malignancy is determined by intrinsic invasive properties of cancer cells and extrinsic signals
from the local tumor microenvironment. Cancer cells acquire invasive properties in the process of
epithelial-mesenchymal transition (EMT) [3]. It elevates their capability of penetrating tissue barriers
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and of entering the circulation in a process of diapedesis [4–6]. Notably, the interrelations between
the invasiveness and drug-resistance of cancer cells have been reported. They are responsible for the
relative inefficiency of currently available therapeutic approaches against malignant lung cancers.
Consequently, drug-resistant cancer cells selectively disseminate throughout the organism, leading to
cancer relapses after the cessation of treatment. These facts stress the necessity for the elaboration of
new anti-cancer strategies that would bypass the limitations of conventional chemotherapy. Because the
speed of diapedesis limits the efficiency of the malignant dissemination of cancer cells [7,8], cancer cell
diapedesis is a promising therapeutic target.
During the diapedesis, circulating cancer cells progressively adhere to the endothelium and
locally activate endothelial cells via paracrine and juxtacrine signaling [8]. The efficiency of
endothelial activation is determined by the quality and quantity of intercellular communication
networks constituted between cancer and endothelial cells [8–10]. Paracrine, juxtacrine, and gap
junction-mediated signals disrupt the endothelial layer in the proximity of cancer cells, thus facilitating
their selective transmigration and homing in adjacent tissues. The active contribution of endothelium
in cancer cell diapedesis [9,11] opens perspectives for introducing the drugs that would interfere with
the intercellular signaling involved in endothelial activation. Prospectively, such a strategy would help
to bypass the drug-resistance of cancer cells.
Fenofibrate (propan-2-yl 2-{4-[(4-chlorophenyl) carbonyl]phenoxy}-2-methylpropanoate; FF) has
recently been suggested for metronomic strategies targeted at the diapedesis of circulating cancer
cells [12–18]. FF is an FDA-approved vasoactive drug [19,20], applied to normalize serum levels of
triglycerides and cholesterol, and to improve the HDL:LDL ratio [21–24]. In addition to the “canonical”
(hypolipidemic) activity of FF, its interference with neoplastic and invasive properties of cancer cells
has been described. We have previously demonstrated that FF attenuates endothelial susceptibility to
the signals generated by prostate cancer cells. Thus, FF reduces the efficiency of prostate cancer cells
diapedesis [9]. FF also interferes with primary tumor vascularization and the subsequent metastatic
cascade via cytostatic effects on endothelial cells [19,25–29]. Multifaceted FF activities are related to the
activation of peroxisome-proliferator activated receptor-α (PPARα) and to the PPARα-independent
elevation of reactive oxygen species in the cells (ROS; [30,31]). They prompted us to test the suitability
of FF for the metronomic chemotherapy of advanced lung cancers.
Co-cultures of human umbilical vein endothelial cells (HUVEC) with cancer cells enable the
recapitulation of the events associated with the diapedesis of lung cancer cells. We used this
experimental approach to estimate the effect of FF on the efficiency of this process. In particular,
we analyzed (i) the role of paracrine and Cx43-mediated gap junctional intercellular communication
(GJIC) [32] between HUVECs and lung adenocarcinoma A549 cells during their diapedesis. We also
(ii) identified the mechanisms underlying the interference of fenofibrate with these systems. Finally,
we (iii) estimated the consequences of FF for the selectivity of endothelial barriers during lung cancer
cell diapedesis.
2. Results
2.1. FF Interferes with the Diapedesis of A549 Cells in a PPARα-Independent Manner
Human lung adenocarcinoma A549 cells induce the local disruption of endothelial integrity. This is
illustrated by the disruption of tight (ZO-1+) and adherens junctions in the regions of endothelial
layers situated close to CMRA-labeled cancer cells (VE-cadherin+; Figure 1A; Video S1). In addition to
HUVEC retraction, time-lapse videomicroscopy studies demonstrated the activation of endothelial
cells in the proximity of A549 cells. This is illustrated by increased instantaneous speeds of single
HUVECs in contact with A549 cells (Figure 1B) and increased averaged values of HUVEC speed of
movement, calculated at the population level (Figure 1C). A total of 25 µM fenofibrate (FF) exerted an
inhibitory effect on A549-induced HUVEC motility (Figure 1B,C and Figure S1A) in the absence of any
discernible effect on the motility of A549 cells [33]. Concomitantly, FF counteracted a local disruption of
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endothelial continuum in the proximity of A549 cells, as revealed by immunofluorescence (Figure 1A),
time-lapse videomicroscopy (Video S2), and solute permeability tests (Figure 1D). These vasoprotective
effects of FF were correlated with the inhibition of A549 diapedesis observed in the presence of FF.
Averaged values of the transEndothelial Penetration Index (EPI) decreased from 50% and 87% in
control conditions, to 22% and 62% in the presence of FF (calculated for the 6th and 24th hour of
HUVEC/A549 co-cultivation, respectively; Figure 1E). The inhibitory effect of FF on A549-induced
HUVEC motility (Figure 1B) and A549 transmigration (Figure 1F) was sensitive to ROS scavenger
N-acetyl-L-cysteine (NAC, 1 mM), whereas the PPARα inhibitor (GW6471; 10 µM) had no effect on
these parameters (Figure S1A). Co-cultures of HUVEC/A549 cells recapitulate the events involved in
A549 diapedesis, sothese observations demonstrate that A549 cells locally deteriorate the endothelial
barrier function. FF interferes with A549-induced endothelial cell activation and, consequently, with the
diapedesis of A549 cells in a PPARα-independent/ROS-dependent manner.
2.2. A549 Cells Impair Endothelial Barrier Function via Intercellular Cx43/EGF/ERK1/2-Dependent Signaling
To identify the mechanisms underlying the attenuation of the endothelial barrier function
by A549 cells, we further focused on the mediators of A549-induced HUVEC activation. Protein
array analyses demonstrated the expression of numerous angioactive factors in A549 cells (such as
FGF-2, Serpin E1, and uPA), and the up-regulation of EGF in A549/HUVEC co-cultures (Figure 2A).
Concomitantly, HUVECs displayed increased motility in A549-conditioned medium (Figure 2B and
Figure S1B), which suggests the role of paracrine, EGF-dependent signaling in HUVEC activation
by A549 cells. Notably, we also observed a high functionality of gap junctions in HUVEC continua
(Figure 2C and Figure S2A). This was accompanied by somewhat limited GJIC between A549 cells and
HUVEC, as demonstrated by the relatively low value of a coupling index estimated for HUVEC/A549
co-cultures (Ci = 17.6%). A549-induced activation of HUVECs was correlated with an increased
abundance of connexin(Cx)43+ plaques in HUVEC/A549 co-cultures Cx43 (Figure 2D). Moreover,
the inhibition of Cx43-mediated GJIC by 18-α-glicyrrhetinic acid (AGA; 70 µM, cf. Figure S2C in
Supplementary data) and Cx43 down-regulation by siRNA (Figure S3) led to the distinct attenuation
of HUVEC activation by A549 cells (Figure 2E and Figure S1C,D), in the absence of non-specific effects
of control siRNA (Figure S3). Thus, Cx43-mediated communication between A549 cells and HUVECs
may up-regulate EGF, which further activates HUVECs in a para/autocrine manner. Actually, ectopic
administration of EGF resulted in the activation of HUVECs, whereas chemical inhibition of the EGF
receptor (by PD158780, 20 µM) and of ERK1/2 (by UO126, 50 µM) led to the attenuation of this
process (Figure 2F; Figures S1E,F and S4). Collectively, these data indicate the involvement of the
Cx43/EGF/ERK1/2 axis in A549-induced HUVEC activation.
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Human lung cancer A549 cells (stained with CMRA-Cell Tracker o marked with arrows)
w re seeded onto human umbilical vein endothelial cell (HUVEC) monolayers at the density of
1300 ells/cm2. The ntegrity of endothelial continua, HUVEC motility, and endothelial permeability
was assessed by anti-ZO 1/VE-cadherin immunostaining ((A); 6 h), time-lapse videomicroscopy
((B,C); 7 h), and solute permeability tests (D), respectively, in the absence or in the presenc of 25 µM
fenofibrate (FF). (B,C) shows in tantaneous speeds of single HUVEC in control conditions and in
the presence of A549/25 µM FF, and the comparison of average speeds of HUVEC movement in the
presence of A549 cells/FF/GW6471/NAC, respectively, quantified based on changes in cell centroid
position. (E) The effect of FF on the efficiency of A549 diapedesis (TransEndothelial Penetration; EPI)
was estimated after 6 and 24 h of co-culture. (F) Effect of PPARα inhibitor (GW6471) and ROS scavenger
(N-acetyl-L-cysteine; NAC) on A549 diapedesis (EPI), estimated after 6 h of A549/HUVEC co-culture.
Transmigration of at least 200 A549 cells was analyzed for each group. The statistical significance of the
differences in (C–F) was tested with one-way ANOVA followed by a post-hoc Tukey’s HSD comparison
(* p < 0.05 and ** p < 0.01). Error bars represent SEM. All results are representative of at least three
independent experiments (n ≥ 3). Scale bar = 40 µm. Note that the relatively efficient diapedesis of
A549 cells is considerably inhibited by FF.
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Figure 2. A549 cells impair t e endothelial barrier function via t e activation of the
Cx43/EGF/ERK1/2-dependent intercellular signaling axis. (A) A549 cells were seeded onto HUVEC
monolayers as in Figure 1 and co-cultured for 24 h. Then, the expression of angioactive proteins was
semi-quantitively estimated with an antibody array kit (see Materials and Methods). Plots show the
densitometrically estimated dot intensities, illustrating the protein amounts in A549 cells (in a.u.; left)
or in A549/HUVEC co-cultures relative to the HUVEC control. (B) A549-conditioned medium (3:5)
was added to HUVECs and their motility was estimated with time-lapse videomicroscopy for 7 h.
(C) Calcein-loaded HUVEC (left) or A549 cells (right) were seeded onto HUVEC monolayers and GJIC
(coupling ratio-Ci) was estimated by a calcein transfer assay after 1 h. Concomitantly, Cx43 expression
in HUVECs and in HUVEC/A549 co-cultures was estimated with immunofluorescence (D). (E) The
effect of AGA (70 µM) and Cx43 silencing by siRNA on HUVEC motility. (F) HUVECs were cultured
in the presence of EGF or A549/HUVEC co-cultures were established as above and the effects of EGFR-
or ERK1/2 inhibitor (PD158780 and UO126, respectively) on HUVEC motility were estimated with
time-lapse videomicroscopy. Error bars represent SEM. Scale bar = 40 µm. The statistical significance
of the differences was tested with one-way ANOVA followed by post-hoc Tukey’s HSD (B,E) or
non-parametric Dunnett comparison (A,F); ** p < 0.01. All results are representative of at least three
independent experiments (n ≥ 3). Note the presence of EGF in A549/HUVEC co-cultures and the
attenuating effect of chemical Cx43/EGFR and ERK1/2 inhibition on A549-induced HUVEC activation.
2.3. FF Interferes with Cx43/EGF-Mediated Signaling between HUVECs and A549 Cells
Further analyses were performed to estimate whether FF can inhibit the diapedesis of A549
cells (Figure 1) through an inhibitory effect on the activity of the Cx43/EGF/ERK1/2-dependent axis.
The comparison of Cx43 levels in the control and FF-treated HUVEC/A549 co-cultures demonstrated
additive effects of A549/FF on endothelial Cx43 expression (Figure 3A and Figure S5A,B). However,
they were accompanied by the attenuating effect of FF on GJIC between A549 and endothelial cells,
as illustrated by the decreased coupling index (Ci) in FF-treated A549/HUVEC co-cultures. It decreased
from 17.6% in control conditions to 3.1% in the presence of FF (Figure 3B and Figure S2B).
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Figure 3. e ofibrate interferes with the co munication networks established between HUVEC
and A549 cells. (A) HUVEC/A549 co-cultures were established as in Fig re 1 and cultivated in
the absence or presence of 25 µM FF. Cx43 levels were a alyze at the indicated time points by
immunoblotting, quantified by densitometry (Figure S5A,B) and visualized by immunofluorescence
after 6 h. (B) Calcein-loaded HUVEC (left) or A549 cells (right) were seeded onto HUVEC monolayers
and the effect of FF on GJIC (coupling ratio-Ci) was estimated by calcein transfer assay after 1 h.
(C) Expression of angioactive proteins in FF-treated HUVEC/A549 co-culture was se i-quantitively
estimated by the antibody array kit. Plots sho the densito etrically estimated dot intensities,
illustrating the a ounts of a given factor in VEC/A549 cells in the presence of 25 µM FF (24 h;
relative to HUVEC/ 549 control). (D) HUVEC/A549 co-cultures were cultivated in the absence or
in the presence of 25 µ FF. Tyr202/204ERK1/2 levels were analyzed at the indicated time points by
immunoblotting and quantified by densito etry (Figure S5C). (E) HUVEC/A549 co-cultures were
established as above and cultivated in the presence of 25 µ FF. The effect of the ERK1/2 inhibitor
(UO126) on HUVEC activation was analyzed with time-lapse videomicroscopy. Error bars represent
SEM. Scale bar = 40 µm. The statistical significance of the differences was tested with one-way ANOVA
followed by post-hoc Tukey’s HSD (B) or non-parametric Dunnett comparison (A–E); * p < 0.05; **
p < 0.01. All results are representative of a least three independent experiments (n ≥ 3). Note that
FF administration inhibits GJIC between cancer and endothelial cells, abolishes the induction of EGF
secretion, and inhibits A549-induced motility of HUVECs.
Concomitantly, FF inhibited GJIC within endothelial continua (Figure 3B) and attenuated the
expression of angioactive factors, in particular EGF, in A549/HUVEC co-cultures (Figure 3C). It also
interfered with A549-induced ERK1/2 activation in HUVECs (Figure 3D and Figure S5C). We also
observed the additive inhibitory effect of FF and ERK1/2 inhibitor (UO126) on HUVEC motility
(Figure 3E and Figure S1E). These data indicate that FF inhibits A549 diapedesis via the interference
with Cx43/EGF/ERK1/2-dependent signaling between HUVECs and A549 cells.
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2.4. FAK/Rac1/RhoA-Dependent Signaling Participates in the Activation of HUVECs by A549 Cells
The endothelial barrier function equally depends on the stability of intercellular contacts and
the adhesion of endothelial cells to the underlying tissues [8]. Notably, stress fibers’ formation and
the maturation of focal contacts were observed in HUVECs co-cultured with A549 cells (Figure 4A).
It confirms that Cx43/EGF/ERK1/2-dependent signaling can disturb the equilibrium between the
adhesion of endothelial cells to their neighbors and to the extracellular matrix.
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HUVECs by A549 cells. (A) 549 cells (marked with arrow) were seeded onto the monolayer of HUVEC
as described in Figure 1, cultivated for 6 h, fixed, and stained for F-actin and vinculin. (B) A549/HUVEC
co-cultures were established as above, and Tyr397, Tyr576/577, and Tyr925 FAK were analyzed at the
indicated time points by immunoblotting and quantified by densitometry (Figure S5D). (C) Cytoskeletal
architecture of HUVEC cultured in co-cultures with A549 cells treated with Rhosin (left) or NSC23766
for 6 h (right). (D,E) A549/HUVEC co-cultures were treated with Rhosin and NSC23766 followed
by the analyses of HUVEC motility (D) and A549 diapedesis ((E); 6 h). Error bars represent SEM.
The statistical significance of the differences was tested with one- ay ANOVA followed by post-hoc
Tukey’s HSD (D,E); ** p < 0.01. All results are representative of at least three independent experiments
(n ≥ 3). Scale bar = 40 µm. Note that RhoA/Rac1-dependent disruption of endothelial continuum by
A549 cells is accompanied by FAK activation and cytoskeletal rearrangements in proximal HUVECs.
To identify the effectors of the Cx43/EGF/ERK1/2-dependent axis during this process,
we focused on the activity of focal adhesion kinase (FAK) and small G proteins in HUVECs.
Increased phosphorylation of this kinase at Tyr397 and Tyr925 was observed in E s after A549
seeding. (Figure 4B; Figure S5D in Supplementary data). Analyses of the involvement of RhoA
in A549-induced HUVEC activation demonstrated that its chemical inhibition by Rhosin (30 µM)
attenuated A549-induced stress fibers formation and the maturation of focal adhesions in HUVECs
(Figure 4C). Concomitantly, Rhosin interfered with A549-induced HUVEC motility (Figure 4D and
Figure S1G) and inhibited A549 diapedesis (Figure 4E). The inhibition of A549-induced cytoskeletal
rearrangements and HUVEC motility was also observed in A549/HUVEC co-cultures treated with
Rac1 inhibitor (NSC23766; 50 µM; Figure 4C,D; Figures S1G and S4). However, NSC23766 had minute
effects on A549 diapedesis (Figure 4E). Collectively, these observations indicate that the A549-activated
Cx43/EGF/ERK1/2-dependent intercellular signaling axis impairs the endothelial barrier function
through FAK/RhoA-dependent HUVEC activation. Rac1-dependent signaling plays an auxiliary role
in this process.
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2.5. FF Directly Attenuates HUVEC Susceptibility to the RhoA/Rac1-Dependent Signaling
FF has previously been shown to augment the endothelial barrier function in the proximity of
cancer cells through the direct augmentation of endothelial cells to underlying ECM [9]. Actually,
accelerated FAK phosphorylation (Figure 5A and Figure S5E) and augmented maturation of endothelial
focal adhesions were observed in FF-treated A549/HUVEC co-cultures (Figure 5B), despite the
inhibitory effect of FF on Cx43/EGF/ERK1/2 intercellular signaling between A549 cells and HUVECs
(Figure 4).
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Concomitantly, the up-regulation of 3 and 4 integrin as observed in FF-treated HUVECs,
whereas A549 cells induced the expression of α4, αv, β1, β3, β4, and β5 integrin in these cells (Figure 5C
and Figure S5F). Furthermore, HUVECs displayed relatively low susceptibility to Rac1/RhoA
inhibitors (NSC23766 and Rhosin, respectively) when cultivated in FF-treated co-cultures with A549
cells. This is illustrated by the negligible effects of both agents on FF-augmented HUVEC adhesion
(Figure 5D) and FF-inhibited A549 diapedesis (Figure 5E). Only a slightly enhanced maturation of
focal contacts was seen in the presence of Rhosin, which correlated with the inhibition of HUVEC
motility (Figure 5F and Figure S1G). These observations suggest that FF attenuates the susceptibility
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of HUVECs to A549-induced activation of Rac1/RhoA-dependent signaling, thus augmenting their
barrier function.
2.6. FF Selectively Impairs Transendothelial Migration of FibroblastoidA549 Cells
To estimate the biological significance of the augmenting effect of FF on the endothelial barrier
function, we further analyzed the selectivity of FF-treated endothelial barriers. For this purpose,
we focused on the phenotype of A549 cells that most readily transmigrated through HUVEC-covered
microporous membranes. Attenuation of A549 diapedesis, observed in the presence of FF (Figure 1),
was accompanied by the decreased efficiency of A549 transmigration through HUVEC-covered
microporous membranes (from 2.65% to 1.12% for native HUVECs; and to 0.04% when HUVECs were
pre-treated with FF for 6 h; Figure 6A).
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A549 cells co prise fibroblastoid and epithelioid sub-populations [34]. Therefore, e further
co pared the numbers of fibroblastoid and epithelioid cells in the progenies of A549 cells that
most readily migrated through HUVEC-covered membranes. A549 cells which transmigrated in
the control conditions gave rise to the progeny that was enriched in fibroblastoid cells (Figure 6B).
o ever, a considerably higher fraction of epithelioid cells as found in the progenies of A549 cells
trans igrating in the presence of FF. As already entioned, no differences ere observed in the
otility of A549 cells propagated in different conditions (Figure 6C), even though a slight dispersion
of epithelioid A549 micro-clones was seen in the presence of FF (Figure 6D). Therefore, this effect could
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hardly be ascribed to the increased motility of epithelioid A549 cells. Collectively, these data indicate
that the augmenting effect of FF on the endothelial barrier function selectively inhibits the diapedesis
of malignant, fibroblastoid A549 cells.
3. Discussion
To form metastases, invasive lung cancer cells must negotiate numerous tissue barriers and
withstand defense responses of the organism. Consequently, lung cancer metastases are preferably
formed by the progenies of the cells that have gone through numerous cycles of pre-selection.
These cells display high adaptability to adverse tissue conditions, relatively high drug-resistance,
and invasive potential. This enforces the introduction of aggressive doses of chemotherapeutics that
promote a selective expansion of aggressive cancer cell subpopulations and evoke systemic adverse
effects. A way out of this vicious circle is given by the metronomic approaches focused on reducing the
susceptibility of normal cells to the signals from cancer cells. Importantly, such approaches bypass the
drug-resistance of cancer cells without provoking the selection of malignant cancer cell lineages. Here,
we described PPARα-independent/ROS-dependent inhibitory effects of 25 µM FF on intercellular
signaling between endothelium and lung cancer cells during their diapedesis. This FF concentration
remains within the range of maximal serum concentrations of fenofibric acid (an active FF metabolite)
in the sera of FF-treated patients [35–37]. Due to the crucial role of diapedesis for lung cancer metastasis,
our findings open perspectives for the application of this well-tolerated, FDA-approved drug in the
treatment of advanced lung cancers.
Extravasation of circulating cancer cells is the final step of their systemic dissemination and
the initial point of secondary tumors’ formation [8]. Our data indicate that the diapedesis of A549
cells is initiated by the orchestrated action of GJIC and paracrine signals exchanged between cancer
and endothelial cells. The role of cooperative Cx43/EGF-mediated intercellular signaling in this
process is illustrated by attenuated endothelial activation in AGA-treated A549/HUVEC co-cultures,
the activation of HUVECs upon ectopic EGF administration, and similar HUVEC reactions to PD158780
in the presence of A549 cells and EGF. Accordingly, Cx43/EGF interferes with the endothelial barrier
function through the activation of proximal endothelial cells, whereas ErbB2/4, which is also a
target for PD158780, does not participate in this axis. Cx43/EGF up-regulation in endothelial cells
further enhances intercellular cooperation within the endothelium, thus facilitating endothelial cells’
activation. Additional studies are necessary to elucidate the mechanism underlying A549-induced
endothelial Cx43 up-regulation. We have previously shown that endothelial Cx43 up-regulation is
accelerated in the proximity of cancer cells that have undergone ectopic Cx43 down-regulation [11].
Therefore, two peaks of Cx43 up-regulation in A549/HUVEC co-cultures may illustrate the consecutive
involvement of Cx43-independent and Cx43-dependent mechanisms in this phenomenon. Increased
ERK1/2 phosphorylation levels observed during A549 diapedesis and impairment of this process by
chemical ERK1/2 inhibition reveals a novel intercellular Cx43/EGF/ERK1/2-dependent signaling axis,
which is crucial for lung cancers’ diapedesis. A corresponding Cx43/Akt/ERK1/2/FAK-dependent
intercellular pathway has been shown to participate in the diapedesis of prostate cancer cells [9].
Notably, the activation of FAK in A549/HUVEC co-cultures was accompanied by attenuating effects
of chemical RhoA/Rac1 inhibition on A549-induced HUVEC activation. Even though the specificity
of chemical inhibitors may be limited, these findings indicate that Cx43/EGF/ERK1/2 signaling
interferes with the endothelial barrier function via FAK/RhoA/Rac1-dependent deregulation of the
balance between endothelial adhesion, contractility, and motility [38].
In our hands, FF interfered with the diapedesis of lung cancer cells via the ROS-dependent
inhibition of cooperative Cx43/EGF/ERK1/2-dependent signaling between lung cancer and
endothelial cells. This notion is confirmed by the attenuating effect of NAC on the FF-induced inhibition
of A549 diapedesis and by reduced levels of Cx43-mediated GJIC, EGF production, and ERK1/2
phosphorylation in FF-treated A549/HUVEC co-cultures. These findings remain in contrast to our
previous data [9]. They revealed FF-resistance of a corresponding, Cx43/Akt/ERK1/2/FAK-dependent
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loop, established between extravasating prostate cancer and endothelial cells. Moreover,
different patterns of integrin up-regulation and FAK activation were observed in FF-treated HUVECs
and in HUVEC/A549 co-cultures. Thus, FF exerts a direct cytoprotective effect on HUVECs,
in addition to its indirect effect on the communication loops between cancer and endothelial cells.
Corresponding protective effects of FF on endothelial cells have already been described in vitro and
in vivo [12–18]. In our hands, Rac1/RhoA inhibitors had negligible effects on FF-inhibited HUVEC
motility and A549 diapedesis, showing that FF attenuates HUVEC susceptibility to A549-activated
FAK/RhoA/Rac1-dependent signaling. These findings confirm that FF augments endothelial adhesion
through direct interference with small G protein-dependent cell activation. This effect of FF augments
the endothelial barrier function in the proximity of lung cancer cells.
Collectively, our data show the multifaceted augmenting activity of FF on the endothelial barrier
function in the proximity of A549 cells. We have identified the intercellular signaling pathway that
determines the diapedesis of lung cancer cells. We also revealed the mechanisms underlying the
interference of FF with this pathway. Accordingly, connexin(Cx)43-dependent intercellular signaling
between A549 cells and HUVECs induces Cx43 expression and the production of EGF in endothelial
cells. EGF further activates HUVECs in an ERK1/2-dependent manner and attenuates the endothelial
barrier function. Apparently, Cx43 up-regulation within the endothelial continuum facilitates the
intracellular propagation of EGF-dependent signals, thus amplifying Cx43/EGF/ERK1/2-dependent
signaling throughout proximal endothelium. Other endothelial connexins, including Cx37 and
Cx40, may also be involved in this process, even though they are down-regulated in activated
endothelia [39]. Consequent activation of FAK/Rac1/RhoA-dependent signaling disturbs the balance
between the adhesion, contractility, and motility, which is characteristic of stationary endothelial cells.
Thus, it impairs the endothelial barrier function and facilitates cancer cell diapedesis. FF interferes
with lung cancer cells’ diapedesis through the activation of ROS-dependent signaling that inhibits
the Cx43/EGF/ERK1/2-dependent signaling axis. Concomitantly, it reduces the susceptibility of
endothelial cells to FAK/RhoA/Rac1-dependent signaling, thus stabilizing endothelial barriers.
Notably, these multifaceted activities of FF lead to the selective transmigration of A549 cells,
as illustrated by the reduced fraction of potentially malignant, fibroblastoid cells in the progeny
of transmigrating A549 cells. Identification of the mechanisms responsible for this effect remains
beyond the scope of this study. However, this effect may additionally impair the metastatic cascade of
lung cancer.
Chemotherapeutic strategies focused on the augmentation of tissue barrier functions and/or
on the interference with the intercellular communication systems between cancer and endothelial
cells are considered as an attractive alternative for traditional chemotherapy. Our data show
that FF efficiently interferes with communication networks between lung cancer and endothelial
cells, thus potentially inhibiting lung cancer progression. They are consistent with the long list
of inhibitory effects of FF on the malignancy of glioma/glioblastoma [29,40], hepatoma [30,41],
medulloblastoma [42], melanoma [25,43], and prostate cancer cells [44]. Concomitant augmentation
of the endothelial barrier function during the diapedesis can additionally reduce the risk of lung
cancer metastases. The application of FF may help to bypass the drawbacks of conventional lung
cancer chemotherapy, which are related to systemic adverse effects and to the microevolution of
drug-resistant cells. This notion is supported by the low toxicity and high systemic tolerance of
fenofibrate, confirmed during decades of its application in the treatment of hyperlipidemia. Studies are
now going on to elucidate the consequences of FF for the microevolution of drug-resistant cancer cell
sub-populations. They should help to assess whether fenofibrate can be used to establish metronomic
treatment regimens of drug-resistant lung tumors.
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4. Materials and Methods
4.1. Cell Cultures
Human umbilical vein endothelial cells (HUVEC; Life Technologies Corporation, Carlsband, CA,
USA) were cultured (up to six passages) in endothelial basal medium (EBM; Lonza, Basel, Switzerland)
supplemented with 10% fetal bovine serum (FBS) and supplement cocktail (hydrocortisone,
recombinant hEGF, bovine brain extract, gentamicin, amphotericin-B; all from Lonza) [9]. Human lung
cancer A549 cells (ATCC CCL-185) were cultured in RPMI-1640 medium (Lonza) supplemented with
10% FBS and antibiotics [34]. For co-culture experiments, lung cancer cells were seeded onto HUVEC
monolayers (at 70% (cf. 4.3) and 98% confluence (cf. 4.2, 4.4, 4.5,4.6, 4.7)) at the density of 1300 cells/cm2.
The behavior of HUVEC and A549 cells was analyzed in serum-free EBM medium supplemented with
EGF (20 ng/mL; 10605HNAE250, Thermo Fisher Scientific, Waltham, MA, USA), PPARα inhibitor
(GW6471; 10 µM; G5045, Sigma, Saint Louis, MO, USA), EGFR inhibitor (PD158780; 20 µM [45,46];
ab141267, Abcam, Cambrige, UK), RhoA inhibitor (Rhosin; 30 µM [46]; 555460, Merck Millipore,
Burlington, VT, USA), Rac1-inhibitor (50 µM [47]; NSC23766; 553502, Merck Millipore), ERK1/2
inhibitor (UO126; 50 µM [48]; M 62005, Merck Millipore), 18-α-glicyrrhetinic acid (AGA; 70 µM; G8503,
Sigma), fenofibrate (FF; 25 µM F6020, Sigma), and N-acetyl-L-cysteine (NAC; 1 mM; A9165, Sigma).
Chemical inhibitors were administrated at the time points indicated in the text and at the concentrations
that secure their specific action and the lack of cytotoxic effects (Figure S4). Cell viability was estimated
with the Trypan Blue assay (0.4%; Sigma, St. Louis, MO, USA). After trypsinisation (0.25% trypsin,
1 mM EDTA in Ca2+/Mg2+-free PBS; Sigma, St. Louis, MO, USA), the cells were re-suspended in PBS,
mixed with Trypan Blue solution (1:1 v/v), and analyzed in a haemocytometer. A549-conditioned
media (CM) were aspirated from A549 cell cultures after 24 h of incubation, centrifuged (10 min, RT,
1000 rpm), mixed with fresh EBM media (ratio 3:5), and added to HUVEC culture.
4.2. Immunofluorescence and Fluorescence Microscopy
For the immunofluorescence analysis, cells were seeded on coverslips as described above.
Co-cultures were subsequently fixed with 3.7% formaldehyde at room temperature (RT; 20 min) and
permeabilized (0.1% Triton X-100, 5 min). For Cx43 staining, cells were fixed in MetOH/Acetone (7:3)
solution for 10 min at−20 ◦C. Specimens were then blocked with 3% BSA and incubated with a primary
antibody (rabbit polyclonal anti-VE-cadherin (1:200; V1514 Sigma), mouse monoclonal anti-vinculin
(1:200, V9131 Sigma), rabbit polyclonal anti-TJP1 (ZO-1; 1:200, HPA001636 Sigma), or rabbit polyclonal
anti-Cx43 antibody (1:200; C6219; Sigma)) for 1 h. Next, the cells were stained with secondary antibody
(AlexaFluor®488-conjugated goat anti-mouse IgG (1:300, A11029), AlexaFluor®488-conjugated goat
anti-rabbit IgG (1:300, A11008), AlexaFluor®546-conjugated goat anti-mouse IgG (1:500, A11003);
all from Thermo Fisher Scientific), or AlexaFluor®488-conjugated phalloidin (1u/slide, A12379 Thermo
Fisher Scientific), and counterstained with Hoechst 33358 (0.5 µg/mL, B2883 Sigma). Where indicated,
A549 cells were stained with CellTracer Orange CMRA according to the manufacturer’s protocol
(10 µM, C34551 Thermo Fisher Scientific). Image acquisition was performed with the Leica DMI6000B
microscope (DMI7000 version, Leica Microsystems, Wetzlar, Germany) equipped with the Total Internal
Reflection Fluorescence (TIRF) and Nomarski Interference Contrast (DIC) modules.
4.3. Cell Motility
The movement of HUVECs in the control condition and in co-cultures with A549 cells was
time-lapse recorded using the Leica DMI6000B videomicroscopy system equipped with a temperature
chamber (37 ◦C/5% CO2), IMC contrast optics, and a CCD camera. HUVECs were seeded at a density
of 500 cells/cm2 and cultured for four days to form islets. Then, their movement was recorded for
7 h with 5 min intervals in the absence (control) and the presence of A549 cells (1300/cm2) for 7 h.
Only HUVECs that had direct contact with A549 cells at the onset of registration were analyzed [11].
The tracks of individual cells were determined from a series of changes in the cell centroid positions.
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The data were pooled and analyzed to estimate the averaged total length of the cell trajectory (i.e.,
the “Distance” covered by the cells during the registration time; µm) and the total length of cell
displacement (“Displacement”, i.e., the distance from the starting point directly to the cell’s final
position; µm), and the average speed of cell movement (Speed; µm/min). Cell trajectories from
no less than three independent experiments (number of cells > 50) were obtained for analysis [49].
Instantaneous velocity (Vi) was calculated at each time point (t) according to the formula: Vi(t) = (d1 +
d2)/2∆t, where d1 and d2 are the distances travelled during two sequential intervals 1 and 2 (between
the frame proceeding and the frame following t, respectively), and ∆t is the time interval between
successive frames.
4.4. Transendothelial Penetration and Permeability Analyses
HUVECs were seeded on coverslips at 2 × 104 cells/well and grown to confluence for 72 h.
Thereafter, A549 cells (1300/cm2) stained with CellTracer Orange CMRA (10 µM, Life Technologies)
were seeded on HUVEC monolayers and incubated for 6 h and 24 h. Blind microscopic estimation of the
percentage of A549 lung cancer cells capable of disrupting the endothelial continuum (transEndothelial
Penetration Index-EPI) was performed on F-actin/DNA stained specimens. Transmigration of at
least 200 A549 cells was analyzed for each group [50]. For the permeability assay, HUVEC were
seeded on Transwell inserts (3 µm pore size, 6.5 mm diameter; Corning) at 1 × 105 cells/insert
and non-adherent cells were removed after 6 h. After three days of culture, FF and/or A549 cells
were applied to the upper compartments of Transwells in serum-free and phenol red-free medium,
followed by the application of FITC-Dextran (MW 42000, 1 mg/mL; after 6 h). Medium samples were
taken from the lower compartment after 15, 30, and 60 min and equal volumes of the medium were
re-added to the lower chamber. The amount of FITC-Dextran was determined in the samples with an
Infinite M200PROmicroplate reader (Tecan Group Ltd., Männedorf, Switzerland), using the excitation
wavelength of 492 nm and emission detection at 521 nm [9].
4.5. Immunoblots and Array Analyses
Angiogenesis-related protein expression was semi-quantitatively estimated with an antibody
array kit (Proteome ProfilerTM Human Angiogenesis Array Kit, R&D Systems, Minneapolis, MN,
USA), according to the manufacturer’s protocol. Samples were mixed with a cocktail of biotinylated
antibodies and then applied onto nitrocellulose membranes to allow their binding to cognate
immobilized capture antibodies. Complexes were detected with a streptavidin-HRP system and
quantified with the MicroChemii imaging system (Quantity One 1-D Analysis Software, Hercules,
CA, USA). The signal was produced at each spot in proportion to the amount of the analyte bound.
The results were expressed as the mean pixel density (A549) or fold changes above or below the
control indicated in the text. For immunoblot analyses, the cells were dissolved in lysis buffer and
cellular proteins (20 µg/lane) were applied to 10% or 15% SDS-polyacrylamide gels, which was
followed by transfer to the nitrocellulose membrane. Then, the membranes were exposed to primary
antibodies (rabbit polyclonal anti-Cx43 (1:4000; C6219 Sigma), mouse monoclonal anti-α-tubulin
(1:2000; T9026 Sigma) IgG, rabbit anti-pERK1/2 (Thr202/Tyr204; 1:000; 9101 Cell Signaling, Danvers,
MA, USA) IgG, rabbit anti-ERK1/2 (1:1000; 9102 Cell Signaling) IgG, rabbit anti-FAK (1:1000; 3285
Cell Signaling) IgG, rabbit anti p-FAK (Tyr397, 1:1000; 3283 Cell Signaling) IgG, rabbit anti-p-FAK
(Tyr576/577, 1:1000; 3281 Cell Signaling) IgG, rabbit anti p-FAK (Tyr925, 1:1000; 3284 Cell Signaling) IgG,
and rabbit anti-integrin panel (1:1000; 4749 Cell Signaling)), followed by the application of the relevant
HRP-labeled secondary antibodies (Life Technologies). HRP activity was detected with LuminataTM
Crescendo Western HRP Substrate (Merck Millipore). Total protein analyses were performed on the
membranes previously used for the analyses of phosphorylated proteins, subjected to stripping with
Western Blot Stripping buffer (RestoreTMPlus, Thermo Fisher Scientific) [9].
Cancers 2018, 10, 363 14 of 17
4.6. Calcein Transfer Assay
Acceptor HUVEC cells grown in Petri dishes were pre-incubated with FF (25 µM) for 4 h and
calcein (Life Technologies, C3099)-loaded donor A549 cells/HUVECs were seeded onto the monolayers
of HUVEC cells. After 1 h, calcein transfer from donor to acceptor cells was evaluated using a
Leica DM IRE2 inverted fluorescence microscope. Gap junctional intercellular coupling (GJIC) was
quantified as the percentage of donor cells, which successfully coupled with the acceptor monolayer
(coupling index-Ci). Dye transfer from at least 200 donor cells per single coverslip was analyzed in
threeindependent experiments [51].
4.7. Cx43 Silencing by siRNA
A549 cells were seeded at a density of 7 × 104 cells/well into 12-well plates in antibiotic-free
RPMI-1640 culture medium supplemented with 10% FBS. After 24 h, the cells were transfected with
MISSION®GJA1 (EHU105621; 114 pmol; Sigma) or control siRNA (sc-37007, Santa Cruz; 50 nM) using
LipofectamineTM2000 (11668019; Invitrogen) according to the manufacturer’s protocol.
4.8. Transmigration and Microclone Assay
HUVECs were seeded on Tranwell inserts (8 µm pore size, 6.5 mm diameter; Corning, NY, USA)
at a density of 1 × 105 cells/insert and non-adherent cells were removed after 6 h. After threedays
of incubation, A549 cells were seeded 1 × 104 onto HUVEC-covered microporous membranes
and allowed to transmigrate for the next 24 h in control conditions and in the presence of FF.
The TransEndothelial penetration Index (TEI) was estimated as the percentage of seeded cells that
penetrated microporous membranes. Where indicated, HUVECs were pre-incubated with 25 µM FF
for 6 h before A549 seeding. Progeny of the cells that penetrated the membranes were propagated
in standard culture conditions and used for the endpoint experiments. A549 sub-populations cells
were seeded at the density of 500 cells/cm2 and cultivated for 96 h, and the single-cell-derived
microclones were analyzed using the Leica DM IRE2 microscope based on their epithelioid (compact)
and fibroblastoid (dispersed) phenotype. The movement of individual cells in the clones was time-lapse
recorded for 12 h and the average speed of cell movement (Speed, µm/min) was determined based on
the series of changes in the cell centroid position. To compare the sensitivity of established A549 cell
sub-populations to FF, the morphology of epithelioid clones was analyzed in control conditions and
after 24 h-long incubation in the presence of 25 µM FF using the Leica DMI6000B time-lapse system
(Leica Microsystems, Wetzlar, Germany).
4.9. Statistical Analysis
All data were expressed as mean ± SEM from at least three independent experiments (n = 3).
The statistical significance was tested with one-way ANOVA followed by post-hoc Dunnett’s or
Tukey’s comparison for variables with a non-normal (tested with Levene’s comparison) and normal
distribution, respectively. Statistical significance was shown at #,* p < 0.05; ##,** p < 0.01.
5. Conclusions
Collectively, our data show that lung cancer cells locally activate adjacent endothelium and impair
the endothelial barrier function via cooperative gap junction-dependent and paracrine signaling.
Fenofibrate impairs communication between lung cancer and endothelial cells and directly augments
endothelial cell adhesion, thus selectively impairing the diapedesis of malignant lung cancer cells.
Thus, FF can be used for metronomic treatment of lung cancer in elderly patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/10/
363/s1, Figure S1: Single cell analyses of HUVEC motility, Figure S2: Gap junctional intercellular coupling in
A549/HUVEC populations, Figure S3: Effect of Cx43siRNA and control siRNA on Cx43 expression in A549
cells, Figure S4: Effect of chemical inhibitors on the viability and instantaneous speeds of HUVECs, Figure S5:
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Densitometric evaluation and statistical analysis of immunoblot data; Video S1: Diapedesis control; Video S2:
Diapedesis FF.
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